Abiopharma

🔍 Kaseta Michael (Executive)

Company: Liquidia Corp (LQDA)

Report Date: 2026-04-14

Detailed Transactions and Holdings:

• Acquired 3,000 shares of Common Stock at $2.79 per share (Direct)
  Date: 2026-04-14 | Code: M | equity_swap_involved: 0 | shares_owned_after: 408,775.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,000 shares of Common Stock at $40.0 per share (Direct)
  Date: 2026-04-14 | Code: S | equity_swap_involved: 0 | shares_owned_after: 405,775.00 | transaction_form_type: 4 | Footnotes: F2, F1
• Sold 9,044 shares of Common Stock at $40.1409 per share (Direct)
  Date: 2026-04-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 396,731.00 | transaction_form_type: 4 | Footnotes: F3, F4, F1
• Acquired 86,971 shares of Common Stock at $2.79 per share (Direct)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 483,702.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 86,971 shares of Common Stock at $40.1409 per share (Direct)
  Date: 2026-04-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 396,731.00 | transaction_form_type: 4 | Footnotes: F5, F4, F1
• Sold 43,375 shares of Common Stock at $40.1409 per share (Direct)
  Date: 2026-04-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 353,356.00 | transaction_form_type: 4 | Footnotes: F6, F4, F1
• Sold 3,000 shares of Incentive Stock Option (right to buy) at $2.79 per share (Derivative)
  Date: 2026-04-14 | Code: M | Expires: 2030-11-30 | Exercise: 2024-11-30 | equity_swap_involved: 0 | shares_owned_after: 97,505.00 | transaction_form_type: 4 | Footnotes: F7
• Sold 86,971 shares of Incentive Stock Option (right to buy) at $2.79 per share (Derivative)
  Date: 2026-04-15 | Code: M | Expires: 2030-11-30 | Exercise: 2024-11-30 | equity_swap_involved: 0 | shares_owned_after: 10,534.00 | transaction_form_type: 4 | Footnotes: F7

Footnotes:

• F1: Includes (i) 23,375 unvested restricted stock units ("RSUs") of the 124,667 RSUs granted to the Reporting Person on January 11, 2023, (ii) 40,797 unvested RSUs and 21,875 unvested RSUs of the 93,250 RSUs and 50,000 RSUs granted to the Reporting Person on January 11, 2024 and January 15, 2024, respectively, (iii) 77,547 unvested RSUs of the 112,797 RSUs granted to the Reporting Person on January 11, 2025, (iv) 59,320 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4 and (v) 2,650 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan ("ESPP").
• F2: Represents the subsequent sale of the underlying shares from the exercise of stock options on April 14, 2026 reported on this Form 4. Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025.
• F3: Represents the subsequent sale of shares acquired under the ESPP reported on this Form 4. Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025.
• F4: Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $40.00 to $40.39. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: Represents the subsequent sale of the underlying shares from the exercise of stock options on April 15, 2026 reported on this Form 4. Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025.
• F6: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025.
• F7: The option vested over a four-year period with 25% vesting on November 30, 2021 and the remaining 75% vesting ratably on a monthly basis over three years thereafter and became fully vested on November 30, 2024.